LLY
NYSE · Pharmaceuticals
Eli Lilly and Co.
$948.45
-26.51 (-2.72%)
LLY News30 articles
Novo Nordisk Shares Surge on Strong Wegovy Pill Sales, Upgraded 2026 Outlook
Novo Nordisk raised its 2026 guidance after Wegovy pill prescriptions topped 2 million, sending shares up 9.2%. The company now expects a smaller decline in sales and profit this year.
Cabaletta Bio Surges 32% on Early Cell Therapy Data and $150M Financing
Cabaletta Bio shares surged 32% on early cell therapy data and a $150M stock offering. Two of four patients showed clinical activity with rese-cel.
Caterpillar Earnings Propel Dow's 700-Point Surge Amid Mixed Market Signals
The Dow Jones surged nearly 700 points midday Thursday, led by a 10% jump in Caterpillar shares after strong quarterly results, while tech stocks lagged amid inflation concerns.
Dow Surges 700 Points as Earnings Power Stocks Toward Best Month Since 2020
The Dow Jones surged 700 points on Thursday, leading a broad rally as strong corporate earnings pushed major indexes toward their best monthly gains since 2020, shrugging off oil price concerns.
Eli Lilly Lifts 2026 Guidance After GLP-1 Sales Surge 56% in Q1
Eli Lilly boosted its 2026 revenue outlook by $2 billion after Q1 sales jumped 56% to $19.8 billion, propelled by Mounjaro and Zepbound. The company also launched oral GLP-1 pill Foundayo.
Biogen Lowers 2026 Profit View Despite Q1 Beat; Leqembi Sales Soar 74%
Biogen lowered its 2026 adjusted earnings outlook to $14.25-$15.25 per share after Q1 results topped estimates. Leqembi sales jumped 74% to $168M globally.
Hims & Hers Surges on JPMorgan Upgrade and GLP-1 Expansion
Hims & Hers stock jumped 9% after JPMorgan gave an overweight rating and $35 target. The company now offers Eli Lilly's Zepbound and Foundayo through LillyDirect.
Lilly's Oral Obesity Drug Foundayo Trails Novo Nordisk's Wegovy in Early Prescription Data
Eli Lilly's Foundayo prescriptions hit 3,707 in week two, well behind Novo Nordisk's Wegovy. Lilly shares dropped 4%, while Novo gained 6%. Analysts advise caution on early figures.
Novo Nordisk Wegovy Pill Prescriptions Surge Past Eli Lilly's Foundayo in Early Launch Race
Novo Nordisk's Wegovy pill recorded 18,410 U.S. prescriptions in its second week, far outpacing Eli Lilly's Foundayo at 3,707, according to IQVIA data. Novo shares rose, Lilly fell.
Hims Expands Branded GLP-1 Access with Lilly's Zepbound and Foundayo
Hims & Hers Health now offers Eli Lilly's Zepbound and Foundayo via LillyDirect, broadening its branded GLP-1 lineup amid a competitive cash-pay market.
Amazon's GLP-1 Launch Pressures Hims & Hers, Telehealth Rivals
Shares of Hims & Hers Health dropped Tuesday after Amazon launched a GLP-1 weight-management program, heightening competition in the telehealth sector. The company is pivoting from compounded drugs to FDA-approved branded medications.
Lilly's $7B Kelonia Buy Targets In Vivo CAR-T Cancer Therapy
Eli Lilly will purchase Kelonia Therapeutics in a deal worth up to $7 billion, gaining an in vivo CAR-T therapy currently in Phase 1 trials for multiple myeloma.
Pfizer Gains on FDA Priority Review for Padcev as Pipeline Pivots Post-COVID
Pfizer shares advanced after the FDA granted priority review for its Padcev bladder cancer therapy, setting an August decision. Investors await Q1 results to gauge progress in oncology and obesity drugs against fading COVID sales.
Lilly Acquires Kelonia in $7B Bet on In-Body CAR-T Cancer Therapy
Eli Lilly will purchase Kelonia Therapeutics in a deal valued at up to $7 billion, gaining an experimental in-body CAR-T therapy for blood cancer. Lilly shares rose 2.5% on the news.
Major Investors Reduce Pfizer Holdings Amid Growth Transition
Three institutional investors trimmed their Pfizer positions by a combined 740,174 shares in the fourth quarter, filings show, as the pharmaceutical giant navigates its post-pandemic transition.
Pfizer Shares Reach New Peak Amid Divergent Views on Future Growth
Pfizer shares surged to a 52-week high of $28.30, driven by robust quarterly results and promising oncology data. Analysts remain divided on whether the stock's rally is sustainable given looming growth challenges.
Eli Lilly Inks $2.75B AI Drug Deal, Posts Positive Trial Data
Eli Lilly has entered a licensing deal with Insilico Medicine potentially worth $2.75 billion and reported strong late-stage clinical results for its immunology and obesity drugs.
Novo Nordisk Shares Dip Despite FDA Nod for Higher-Dose Wegovy
Novo Nordisk shares declined in Copenhagen trading even after U.S. regulators cleared a higher-dose version of its Wegovy obesity treatment. Competitive pressures from Eli Lilly and looming generic competition in India weighed on investor sentiment.
Eli Lilly's Retatrutide Hits Phase 3 Goals, Stock Pressured by Pricing Concerns
Eli Lilly announced its experimental drug retatrutide achieved primary goals in a Phase 3 trial, significantly reducing blood sugar and weight. The stock declined 1.3% to $918.05 amid an HSBC downgrade and ongoing concerns over drug pricing in the U.S. market.
Wall Street Gains as Airlines, Tech Lift Sentiment Ahead of Fed Decision
Major U.S. stock indices rose Tuesday, led by airline and technology shares, as investors awaited the Federal Reserve's policy update. Goldman Sachs cautioned that an oil supply disruption could drag the S&P 500 lower.
Hims & Hers Stock Stabilizes as Novo Deal Shifts Focus to Profitability
Hims & Hers Health shares traded near $23.82 Friday, stabilizing after a week of volatility driven by its new branded obesity drug agreement with Novo Nordisk. The shift from compounded medications raises margin concerns despite reducing regulatory risk.
Pfizer Shares Dip Amid Market Selloff, Weight-Loss Drug Approved in China
Pfizer shares declined 1.6% on Thursday, caught in a broad market downturn. The company navigates falling COVID product revenue while advancing its pipeline, including a new weight-loss drug approval in China.
Hims & Hers Stock Extends Rally on Novo Nordisk Patent Settlement
Shares of Hims & Hers Health continued their ascent following a resolution to a patent conflict with Novo Nordisk, which will reintroduce branded GLP-1 medications to its service. Analysts have upgraded the stock but caution about potential margin pressures.
Pfizer Shares Dip Amid Vaccine Policy Clarity, Eczema Drug Progress
Pfizer shares declined slightly as regulatory scrutiny of mRNA vaccines eased, offset by positive mid-stage trial results for its experimental eczema drug tilrekimig.
Hims & Hers Soars on Novo Nordisk Partnership, Analyst Targets Rise
Shares of Hims & Hers Health skyrocketed approximately 49% over two sessions following a new distribution agreement with Novo Nordisk. The deal resolves a legal dispute and will bring branded GLP-1 drugs to the telehealth platform, leading several analysts to raise their price targets.
AbbVie's Early Obesity Drug Trial Shows Promising Weight Loss Results
AbbVie reported its amylin-based obesity candidate ABBV-295 led to significant weight reduction in an early study, with no serious safety issues observed. The data marks a strategic step for the company as it seeks growth beyond immunology.
Pfizer's Eczema Candidate Tilrekimig Advances, Eyes Dupixent Rivalry
Pfizer announced its experimental eczema drug tilrekimig achieved its main goal in a mid-stage study, showing significant symptom improvement. The company plans to initiate a pivotal Phase 3 trial later this year.
Hims & Hers Shares Jump on Novo Nordisk Partnership Revival
Hims & Hers Health shares surged in premarket trading Monday following reports that Novo Nordisk will resume selling its weight-loss drugs through the telehealth platform. The move marks a reversal from a patent dispute last month.
Zealand Pharma Stock Crashes on Obesity Drug Data Lagging Lilly
Zealand Pharma A/S shares plunged over 32% Friday after mid-stage trial results for its obesity drug candidate petrelintide showed weight loss well behind Eli Lilly's competing therapy, erasing billions in market value.
FDA Issues Second Ozempic Ad Warning to Novo Nordisk in Escalating Scrutiny
The FDA has sent Novo Nordisk a second advertising violation notice in under a month, citing misleading claims for Ozempic. The agency simultaneously warned 30 telehealth companies about compounded GLP-1 drug promotions.